###### Strengths and limitations of this study

-   A strength is that adverse events associated with accidental opioid overdose were collected from population data rather than adverse event reports.

-   This study provides new data to understand the risk of encephalopathy from a larger sample than previously studied.

-   The study investigated a wide range of neurological, respiratory, cardiac and other adverse events over a 10-year period.

-   Analysis of accidental opioid overdoses was limited to overdoses that led to a hospital admission.

-   We controlled for prescription drug use but lacked information on the actual level of drug exposure including illicit drug use.

Introduction {#s1}
============

A rise in opioid-related deaths in British Columbia (BC) contributed to the declaration of a public health emergency in the province.[@R1] Serious morbidity related to opioid overdose, in contrast, has received relatively little attention. The rate of hospitalisations due to opioid overdose in Canada rose by \>30% from 2007--2008 to 2014--2015.[@R2]

Opioid overdose may lead to a range of neurological, respiratory, cardiac or other adverse events. The evidence linking these events to opioid poisoning has primarily, but not exclusively, been limited to case reports. Neurological events include cerebral hypoxia,[@R3] anoxic encephalopathy,[@R6] toxic encephalopathy,[@R7] delayed encephalopathy[@R10] and leukoencephalopathy[@R9] or delayed leukoencephalopathy.[@R15] Respiratory adverse events include adult respiratory distress syndrome (ARDS),[@R4] respiratory failure,[@R20] pulmonary haemorrhage[@R21] and aspiration pneumonia.[@R6] A retrospective cohort study of opioid overdose leading to intensive care unit admission found that most patients admitted experienced respiratory failure requiring mechanical ventilation, approximately 10% died, and among those who died, half experienced hypoxic brain injury.[@R28] Adverse cardiac outcomes may include cardiac arrest,[@R29] ventricular arrhythmia[@R31] and heart failure.[@R22] Other adverse effects related to opioid overdose may include rhabdomyolysis,[@R4] paraplegia or tetraplegia due to spinal cord injury[@R41] and acute renal failure.[@R4]

We investigated neurological, respiratory, cardiac or other adverse outcomes among patients who were admitted to hospital for accidental opioid poisoning from 2006 to 2015 in BC. Our study examined outcomes that occurred during hospital admissions for accidental opioid poisoning and in the 365 days following discharge from admissions for opioid poisoning. We provide the frequency of these adverse events, assess the influence of repeated overdose and investigate whether risk of these outcomes increased over time. We hypothesised that repeated overdose would show a higher risk of adverse events than initial overdoses due to potential cumulative effects of exposure to high-dose opioids, and that risk of adverse events would increase over the period of our study due to increased use of more potent opioids in BC.

Methods {#s2}
=======

Study setting and design {#s2a}
------------------------

We used a retrospective cohort study design to investigate the risk of neurological, respiratory, cardiac and other adverse events during hospital admissions for accidental opioid overdose or in the 1 year following discharge from overdose admissions. The source population for this study consisted of residents of BC who had been registered for provincial medical services for at least 1 year as of any time during 2006--2015.

We investigated outcomes associated with accidental opioid overdose both immediately following an overdose and in the year following an overdose. Our primary analysis focused on outcomes recorded during a hospital admission for an accidental opioid overdose to investigate outcomes immediately following, or shortly after, an overdose. Our secondary analysis focused on outcomes that occurred during the year following discharge from a hospital admission for accidental opioid overdose to investigate events that occurred after a delay following an overdose. Generally, our primary and secondary analyses examined the same neurological, respiratory, cardiac and other adverse events, but in these two different time periods. As described below, however, these two analyses varied in the cohorts studied and the analytical methods used to investigate outcomes.

In our primary analysis, we evaluated whether risk of the study outcomes was increased in repeat admissions for accidental opioid overdose in comparison to initial admissions. For this analysis, we analysed a cohort of patients who had been admitted to hospital during 2006--2015 for an accidental opioid overdose. Accidental opioid overdoses represent a subset of all opioid overdoses, which exclude those identified as resulting from intentional self-harm, therapeutic use (ie, occurred when the drug was used as prescribed) or unknown intent,[@R2] as defined by the International Classification of Disease (ICD), version 10 (diagnostic codes for accidental opioid overdose are found in online [supplementary appendix table S1](#SP1){ref-type="supplementary-material"}). We selected diagnostic codes to identify accidental opioid overdose based on the codes used in a national study by the Canadian Institute for Health Information.[@R2] A validation study that tested ICD codes for opioid poisoning in electronic health records reported a positive predictive value of 81% for opioid overdoses and poisonings, although it did not test all of the codes that we used in our study.[@R44] Only patients who had not experienced any of the study outcomes in the year prior to their overdose admission were included in the study, in order to focus on incident outcomes. Patients were excluded if they had received a diagnosis for non-accidental opioid poisoning in the year prior to their overdose admission or a diagnosis of self-harm in their overdose admission or in the previous year, or if they had previously entered long-term or palliative care (diagnostic codes for exclusions are found in online [supplementary appendix table S2](#SP1){ref-type="supplementary-material"}).
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We conducted a secondary analysis to evaluate whether risk of study outcomes was elevated in the year following an accidental opioid overdose. In contrast to our primary analysis, this analysis focused on a cohort of patients with long-term prescription opioid use. From this cohort, we selected patients who had been hospitalised for an accidental opioid overdose and controls who had not experienced an overdose hospitalisation. We defined a cohort of long-term opioid users to include patients with an episode of prescription opioid analgesic therapy lasting ≥180 days during 2006--2014, where an episode was defined by a series of opioid dispensings with no more than 90 days between the end of the days' supply of one script and the beginning of another. Patients were eligible for selection into the 'overdose cohort' or control group on or after the date of their first dispensing of opioid analgesic medication 180 days into an episode of opioid therapy. Patients were no longer eligible for selection into the study cohort after stopping use of opioid pain medication for a period of 90 days. We used a period of 180 days to define long-term therapy to try to ensure that we were including only patients who were taking these medications over an extended period, with the goal of including patients who were as similar as possible in the overdose cohort and control group. We allowed a grace period between the end of one prescription and the start of another to determine the end of therapy, because some patients might take their medication over a longer period than the recorded days' supply. We expected it would be less common for prescriptions to exceed 90 days, and setting the 'grace period' between prescriptions at 90 days assumed that some patients might continue to take their medication for twice that length of time.

In the secondary analysis, patients with long-term prescription opioid use as described above were selected to enter the overdose cohort, if they were admitted to hospital for an accidental opioid overdose and had been discharged from hospital during 2006--2014. We selected 20 controls for each member of the overdose cohort, matched on sex and age within 2 years. The date of each overdose patient's discharge from hospital following an overdose admission served as a 'cohort entry date' for the overdose patient and that patient's matched controls. Patients were followed for up to 1 year starting the day after each patient's cohort entry date, and study outcomes were assessed during this follow-up period. Patients could enter the study more than once as a member of the overdose cohort and/or as a control, but it was only possible to enter the overdose cohort more than once if a readmission for accidental opioid overdose occurred at least 1 year from a patient's prior overdose hospitalisation. Patients were excluded if they had received a diagnosis of opioid poisoning, self-harm or any of the study outcomes in the year prior to cohort entry, or if they had previously entered long-term or palliative care. Patients were followed from cohort entry date until the earliest of diagnosis with a relevant study outcome, hospital admission or readmission for opioid poisoning, a diagnosis of self-harm, end of provincial health coverage, entry into long-term or palliative care, death, 365 days of follow-up or 31 December 2015.

Data sources {#s2b}
------------

We used de-identified, patient-level administrative health data from BC, which were linked with encrypted patient identifiers, to create the study cohorts and conduct analyses. Medical Services Plan (MSP) data included outpatient diagnoses, while the Canadian Institute for Health Information Discharge Abstract Database included hospital admissions and inpatient diagnoses and procedures. MSP registration data were used to determine study eligibility and to define patient demographics. BC PharmaNet data were used to identify a patient's prescription drug use and use of long-term or palliative care drug plans.

Outcome measures {#s2c}
----------------

The primary outcome in our study was encephalopathy, which was defined by an inpatient hospital diagnosis of anoxic brain damage, toxic encephalopathy or unspecified encephalopathy. Secondary outcomes included ARDS, respiratory failure, pulmonary haemorrhage, aspiration pneumonia, cardiac arrest, ventricular arrhythmia, heart failure, rhabdomyolysis, paraplegia or tetraplegia, acute renal failure and death. We also included a composite outcome, which we defined as a diagnosis of encephalopathy and/or any of the secondary outcomes (diagnostic codes for outcomes are found in online [supplementary table S3](#SP1){ref-type="supplementary-material"}). In our secondary analysis, we added the unplanned outcome of 'serious adverse events', which was defined as hospitalisation or death from any cause, to provide a more comprehensive measure of potential harm. Inpatient hospital data were used to ascertain whether an outcome diagnosis had occurred. Deaths were ascertained with hospital data and MSP registration data.

Covariates {#s2d}
----------

We adjusted our analyses for patient characteristics, including demographic variables, medical history and prescription history. Demographic variables included sex, age category, low-income status and rural residence. Medical history included variables indicating mental or behavioural disorders due to opioid use, stimulant use and other substance use, and variables for a history of psychiatric illness, pneumonia, other respiratory illness, Romano comorbidity score (0, 1--2, ≥3) and cancer (diagnostic codes for medical covariates are found in online [supplementary table S4](#SP1){ref-type="supplementary-material"}). Prescription history included a variable indicating past use of high-dose opioid pain medication (\>90 mg of 'oral morphine equivalents' per day, calculated using conversion factors recommended in a recent review of opioid utilisation studies),[@R45] a variable for lack of any prescription opioid pain medication use (opioid medications are listed in online [supplementary table S5](#SP1){ref-type="supplementary-material"}) and a variable for past use of sedative/hypnotic medication (identified by Anatomical Therapeutic Chemical code N05C). In the secondary analysis, the variable for mental and behaviour disorders due to stimulant use was excluded (due to a low prevalence in the control group), and prescription history consisted of variables for high-dose opioid use (\>90 mg of 'oral morphine equivalents' per day), duration of prescription opioid use (\<1, 1 to \<2, 2 to \<3, 3 to \<4, 4 to \<5 or ≥5 years) and prior sedative use. We used 90 mg of morphine equivalents per day as a cutoff to define high-dose prescription opioid use, because this reflected advice from the College of Physicians and Surgeons of British Columbia to avoid prescribing of doses above this level in most cases not involving patients with active cancer or those receiving palliative care or end-of-life care.[@R46]

Statistical analyses {#s2e}
--------------------

In the primary analysis, we estimated odds ratios to evaluate whether the risk of each outcome was elevated during repeat hospital admissions for accidental opioid overdose in comparison to initial admissions. We used generalised linear models with a logistic link function and a binomial error distribution. Repeat admissions or 'readmissions' were any admissions for accidental opioid overdose that occurred within a year of a discharge for a previous admission. In the same models, we included a series of binary independent variables indicating the year in which each opioid overdose admission occurred, using the first year of the study, 2006, as a reference year. We inferred the odds of each study outcome occurring in association with an opioid overdose in 2015 in comparison to 2006 (based on the variable indicating an overdose occurred in 2015 versus the reference year), as a test of our hypothesis that the risk of the adverse events we investigated may have increased in recent years due to the use of more potent opioids. In a sensitivity analysis related to the outcome of acute kidney failure, we examined trends in diagnosis of acute kidney failure among the general population.

In the secondary analysis, we similarly estimated odds ratios to evaluate whether risk was increased in the 1-year period following a hospital admission for accidental opioid overdose, when compared with controls. The model included a series of binary independent variables for the year in which patients entered the study (according to date of discharge from an overdose patient's overdose admission or corresponding cohort entry date for each control patient), using 2006 as a reference year, to control for time-varying confounding. In additional models, we included interaction terms representing interaction between these 'cohort entry year' variables and a variable indicating whether a patient was in the overdose cohort (the 'exposed' group), as a test for effect measure modification, to investigate whether risk of our study outcomes in the year following opioid overdose was elevated in more recent years.

All regression models used generalised estimating equations to adjust for correlation of observations ('clustering effects') due to multiple observations from the same patients. We had planned to conduct analyses stratified on whether patients had a history of cancer, but due to a smaller than expected sample size, we chose instead to control for cancer as a covariate.

Patient and public involvement {#s2f}
------------------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. As the study used routinely collected administrative health data, there were no study participants to share results with. There are no plans to disseminate the results of the research to the relevant patient community.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

We identified 3235 patients with a total of 3519 hospital admissions involving accidental opioid overdose during 2006 to 2015. After excluding patients lacking 1 year of provincial medical services coverage prior to admission and applying other exclusion criteria (described above), the cohort for our primary analysis included 2433 patients who had experienced 2554 admissions for accidental opioid overdose, of which 121 were readmissions within a year of a previous admission ([table 1](#T1){ref-type="table"}). The age of patients at the time of overdose admission ranged from 1 to 99 years (median 48; IQR 32--61 years). Patients who were readmitted tended to have a poorer health status and were more likely to have been diagnosed with opioid use disorder and have used a high-dose prescription opioid.

###### 

Characteristics of patients admitted to hospital for accidental opioid overdose, 2006--2015

  -------------------------------------------------------------
  Characteristic                   Admission\    Readmission\
                                   n (%)         n (%)
  -------------------------------- ------------- --------------
  Hospitalisations                 2433          121

  *Type of opioid overdose*                      

   Opium                           8 (0.3)       0

   Heroin                          419 (17.2)    15 (12.4)

   Methadone                       401 (16.5)    26 (21.5)

   Synthetic opioids\*             123 (5.1)     7 (5.8)

   Other opioids†                  1101 (45.3)   46 (38.0)

   Unspecified/other opioids       515 (21.2)    34 (28.1)

  *Sex*                                          

   Female                          1134 (46.6)   54 (44.6)

   Male                            1299 (53.4)   67 (55.4)

  *Age (years)*                                  

   \<10                            36 (1.5)      0

   10--19                          80 (3.3)      \<5

   20--29                          371 (15.2)    16 (13.2)

   30--39                          411 (16.9)    19 (15.7)

   40--49                          415 (17.1)    15 (12.4)

   50--59                          477 (19.6)    21 (17.4)

   60--69                          329 (13.5)    36 (29.8)

   70--79                          186 (7.6)     10 (8.3)

   ≥80                             128 (5.3)     \<5

  Low income                       719 (29.6)    35 (28.9)

  Rural residence                  325 (13.4)    17 (14.1)

  *Substance use disorders*‡                     

   Opioids                         192 (7.9)     25 (20.7)

   Sedatives and hypnotics         22 (0.9)      \<5

   Stimulants                      112 (4.6)     9 (7.4)

   Other                           395 (16.2)    35 (28.9)

  *Romano comorbidity score*‡                    

   0                               1380 (56.7)   54 (44.6)

   1--2                            723 (29.7)    40 (33.1)

   ≥3                              330 (13.6)    27 (22.3)

  *Other medical history*‡                       

   Psychiatric illness             931 (38.3)    58 (47.9)

   Pneumonia                       224 (9.2)     27 (22.3)

   Other respiratory illness       473 (19.4)    35 (28.9)

   HIV                             42 (1.7)      \<5

   Hepatitis C                     33 (1.4)      \<5

   Cancer                          172 (7.1)     11 (9.1)

  *Opioid prescription history*§                 

   Methadone                       29 (1.2)      \<5

   Buprenorphine/naloxone          30 (1.2)      \<5

   High-dose opioid for pain       569 (23.4)    33 (27.3)

   No use of opioids for pain      1097 (45.1)   50 (41.3)

  *Other prescription history*§                  

   Sedatives and hypnotics         571 (23.5)    37 (30.6)

   Stimulants                      63 (2.6)      \<5
  -------------------------------------------------------------

Types of opioid overdose correspond to ICD-10 T40.0-T40.4 and T40.6 (some overdoses appear in \>1 category). Readmissions are defined as additional accidental opioid overdose admissions within 365 days of prior admission.

\*Includes buprenorphine, fentanyl, pethidine and tramadol.

†Includes codeine, hydromorphone, morphine and oxycodone.

‡Based on diagnoses at a physician or hospital visit in the 365 days before opioid overdose.

§Based on dispensings in the 180 days prior to opioid overdose. High-dose opioid use is defined by a dispensing of opioid pain medication of \>90 oral morphine equivalents per day. Small cell sizes are denoted as \'\<5\' or 0 as applicable.

For the secondary analysis, we identified a cohort of 247 883 patients with at least one episode of long-term prescription opioid use during 2006--2014. Our secondary analysis included 538 patients discharged following a total of 552 accidental opioid overdose hospitalisations and 11 040 matched controls from the cohort ([table 2](#T2){ref-type="table"}). Ages ranged from 19 to 100 years (median 58; IQR 49--67 years), as no younger patients met the entry criteria for overdose during long-term prescription opioid use. Patients in the overdose cohort had a poorer health status than controls, and notably many patients had a history of psychiatric illness, high-dose prescription opioid use for pain, prescription opioid use of ≥5 years and/or sedative/hypnotic medication use.

###### 

Characteristics of patients discharged from hospital after accidental opioid overdose and matched controls among patients with long-term prescription opioid use (≥180 days), 2006--2014

  ----------------------------------------------------------------------------------
                                                  Overdose patients\   Controls\
                                                  n (%)                n (%)
  ----------------------------------------------- -------------------- -------------
  Number of patients                              552                  11 040

  *Type of opioid overdose*                                            

    Heroin                                        14 (2.5)             n/a

    Methadone                                     43 (7.8)             n/a

    Synthetic opioids\*                           42 (7.6)             n/a

    Other opioids†                                337 (61.1)           n/a

    Unspecified/other opioids                     143 (25.9)           n/a

  *Sex*                                                                

    Female                                        332 (60.1)           6640 (60.1)

    Male                                          220 (39.9)           4400 (39.9)

  *Age (years)*                                                        

    19--29                                        14 (2.5)             269 (2.4)

    30--39                                        41 (7.4)             829 (7.5)

    40--49                                        89 (16.1)            1771 (16.0)

    50--59                                        165 (29.9)           3296 (29.9)

    60--69                                        129 (23.4)           2562 (23.2)

    70--79                                        81 (14.7)            1611 (14.6)

    80--89                                        25 (4.5)             561 (5.1)

    ≥90                                           8 (1.4)              141 (1.3)

  Low income                                      141 (25.5)           2607 (23.6)

  Rural residence                                 95 (17.2)            1807 (16.4)

  *Substance use disorders*‡                                           

    Opioids                                       58 (10.5)            81 (0.7)

    Sedatives and hypnotics                       14 (2.5)             16 (0.1)

    Stimulants                                    17 (3.1)             31 (0.3)

    Other                                         103 (18.7)           284 (2.6)

  *Romano comorbidity score*‡                                          

    0                                             202 (36.6)           6038 (54.7)

    1--2                                          219 (39.7)           3826 (34.7)

    ≥3                                            131 (23.7)           1176 (10.7)

  *Other medical history*‡                                             

    Psychiatric illness                           300 (54.3)           2534 (23.0)

    Pneumonia                                     93 (16.8)            405 (3.7)

    Other respiratory illness                     162 (29.3)           1709 (15.5)

    HIV                                           \<5                  56 (0.5)

    Hepatitis C                                   15 (2.7)             27 (0.2)

    Cancer                                        52 (9.4)             822 (7.4)

  *Opioid prescription history*§                                       

    Methadone                                     7 (1.3)              20 (0.2)

    Buprenorphine/naloxone                        \<5                  \<5

    High-dose opioid for pain                     305 (55.3)           2152 (19.5)

  *Duration of prescription opioid use (years)*                        

    \<1                                           61 (11.1)            1876 (17.0)

    1 to \<2                                      92 (16.7)            2362 (21.4)

    2 to \<3                                      53 (9.6)             1422 (12.9)

    3 to \<4                                      47 (8.5)             1006 (9.1)

    4 to \<5                                      33 (6.0)             797 (7.2)

    ≥5                                            266 (48.2)           3577 (32.4)

  *Other prescription history*§                                        

    Sedatives and hypnotics                       219 (39.7)           2506 (22.7)

    Stimulants                                    10 (1.8)             146 (1.3)
  ----------------------------------------------------------------------------------

Types of opioid overdose correspond to ICD-10 T40.0-T40.4 and T40.6.

\*Includes buprenorphine, fentanyl, pethidine and tramadol.

†Includes codeine, hydromorphone, morphine and oxycodone.

‡Based on diagnoses at a physician or hospital visit in the 365 days before follow-up.

§Based on dispensings in the 180 days prior to follow-up. High-dose opioid use is defined by a dispensing of opioid pain medication of \>90 oral morphine equivalents per day. Small cell sizes are denoted as \'\<5\' or 0 as applicable.

Frequency of adverse events associated with overdose admissions {#s3b}
---------------------------------------------------------------

The number of hospital admissions for accidental opioid overdose more than doubled over the period of our study, from 180 admissions in 2006 to 393 admissions in 2015, including both initial admissions and readmissions ([table 3](#T3){ref-type="table"}). We found that 3% of overdose admissions during this 10-year period included a diagnosis of encephalopathy, and 25% of overdose admissions included at least one of the adverse outcomes included in our composite outcome ([table 3](#T3){ref-type="table"}).

###### 

Number of hospital admissions for accidental opioid overdose and outcomes evaluated during overdose admission, by year

                                                                   2006    2007   2008    2009   2010   2011   2012   2013   2014   2015   2006--2015
  ---------------------------------------------------------------- ------- ------ ------- ------ ------ ------ ------ ------ ------ ------ ------------
  *Overdose hospitalisations (n):*                                                                                                         
    Admission                                                      \~178   166    \~200   211    207    251    274    284    290    372    2433
    Readmission                                                    \<5     6      \<5     15     8      17     15     18     16     21     121
    All                                                            180     172    203     226    215    268    289    302    306    393    2554
  *Type of opioid overdose* [\*](#tblfn11){ref-type="fn"} *(n):*                                                                           
    Heroin                                                         28      27     34      28     28     35     35     56     67     96     434
    Methadone                                                      30      26     36      32     31     36     54     47     65     70     427
    Synthetic opioid†                                              9       \<7    \<7     8      11     10     14     12     19     37     130
    Other opioid‡                                                  80      82     81      109    101    135    143    147    121    148    1147
    Unspecified/other                                              46      41     52      57     53     60     55     56     53     76     549
  *Number of outcomes* [\*](#tblfn11){ref-type="fn"} *(n):*                                                                                
    Encephalopathy                                                 7       \<5    \<5     \<5    \<5    8      14     11     8      17     77
    Respiratory failure                                            \<6     \<6    7       8      7      10     24     16     17     37     134
    Aspiration pneumonia                                           20      17     18      21     33     31     38     30     36     44     288
    Rhabdomyolysis                                                 7       6      10      11     12     10     17     12     19     20     124
    Acute renal failure                                            13      15     9       16     20     25     30     24     34     51     237
    Death in hospital                                              8       \<5    7       7      \<5    7      9      9      12     13     80
  *Composite outcome*§                                                                                                                     
    Admission with ≥1 event                                        42      37     36      50     54     68     87     72     82     109    637
    Total events                                                   69      55     62      76     83     108    150    111    142    199    1055
  *Incidence proportion¶ (%):*                                                                                                             
    Encephalopathy                                                 3.9     n/a    n/a     n/a    n/a    3.0    4.8    3.6    2.6    4.3    3.0
    Respiratory failure                                            n/a     n/a    3.4     3.5    3.3    3.7    8.3    5.3    5.6    9.4    5.3
    Aspiration pneumonia                                           11.1    9.9    8.9     9.3    15.3   11.6   13.1   9.9    11.8   11.2   11.3
    Rhabdomyolysis                                                 3.9     3.5    4.9     4.9    5.6    3.7    5.9    4.0    6.2    5.1    4.9
    Acute renal failure                                            7.2     8.7    4.4     7.1    9.3    9.3    10.4   7.9    11.1   13.0   9.3
    Death in hospital                                              4.4     n/a    3.4     3.1    n/a    2.6    3.1    3.0    3.9    3.3    3.1
  *Composite outcome*†                                                                                                                     
    Admission with ≥1 event                                        23.3    21.5   17.7    22.1   25.1   25.4   30.1   23.8   26.8   27.7   24.9

\*To avoid small cell sizes, less common types of overdose (opium) and outcome (eg, cardiac outcomes) have been omitted, or a value of \'\<5\' was entered for counts and corresponding proportions were listed as 'n/a\'. Where counts \<5 could be deduced, values of \'\<6\' or \'\<7\' have been used or a tilde (\~) was used for approximate values.

†Includes buprenorphine, fentanyl, pethidine and tramadol.

‡Includes codeine, hydromorphone, morphine and oxycodone.

§The 'composite outcome' included encephalopathy, ARDS, respiratory failure, pulmonary haemorrhage, aspiration pneumonia, cardiac arrest, ventricular arrhythmia, heart failure, rhabdomyolysis, acute renal failure or death ('total events' does not equal the sum of the other events reported, because some outcomes included in the composite outcome were not reported separately).

¶Incidence proportion describes the percentage of hospital admissions for accidental opioid overdose in which patients were diagnosed with each type of outcome in each period.

ARDS, adult respiratory distress syndrome.

Adverse events during admissions for accidental opioid overdose {#s3c}
---------------------------------------------------------------

In our primary analysis, we found no evidence of increased risk of encephalopathy during readmission for accidental opioid overdose in comparison to initial admission for accidental opioid overdose (adjusted OR 0.57; 95% CI 0.13 to 2.49) ([table 4](#T4){ref-type="table"}). Women admitted to hospital for accidental opioid overdose had a lower risk of encephalopathy than men (adjusted OR 0.46; 95% CI 0.26 to 0.81) (online [supplementary appendix table S6](#SP1){ref-type="supplementary-material"}). In addition, we observed no increase in risk of either death in hospital or our composite outcome during readmission for accidental opioid overdose, compared with initial admission (adjusted OR 0.86, 95% CI 0.27 to 2.76, for death in hospital, and adjusted OR 0.83, 95% CI 0.54 to 1.26, for the composite outcome). Similarly, results for other secondary outcomes did not indicate any increased risk during readmission for accidental opioid overdose, compared with initial admission ([table 4](#T4){ref-type="table"}).

###### 

Influence of readmission for accidental opioid overdose and year of overdose on neurological, respiratory, cardiac and other outcomes evaluated during overdose admission

                               Events   Opioid overdose readmission   Admissions in 2015 versus 2006\*          
  ---------------------------- -------- ----------------------------- ---------------------------------- ------ ---------------------
  *Primary outcome*                                                                                             
   Neurological:                                                                                                
   Encephalopathy              77       0.52                          0.57 (0.13 to 2.49)                1.12   0.73 (0.28 to 1.89)
  *Secondary outcomes*                                                                                          
   Respiratory outcomes:                                                                                        
   Respiratory failure         134      1.10                          0.93 (0.43 to 2.04)                3.65   3.05 (1.15 to 8.08)
   Aspiration pneumonia        288      0.45                          0.48 (0.21 to 1.08)                1.01   0.88 (0.49 to 1.59)
   ARDS                        19       n/a                           n/a                                n/a    n/a
   Pulmonary haemorrhage       \<5      n/a                           n/a                                n/a    n/a
   Cardiac outcomes:                                                                                            
   Cardiac arrest              56       n/a                           n/a                                n/a    n/a
   Ventricular arrhythmia      5        n/a                           n/a                                n/a    n/a
   Heart failure               28       n/a                           n/a                                n/a    n/a
   Other outcomes:                                                                                              
   Rhabdomyolysis              124      0.64                          0.64 (0.24 to 1.75)                1.33   0.96 (0.38 to 2.43)
   Acute renal failure         237      1.13                          1.07 (0.60 to 1.91)                1.97   1.86 (0.95 to 3.66)
   Paraplegia or tetraplegia   6        n/a                           n/a                                n/a    n/a
   Death in hospital           80       0.77                          0.86 (0.27 to 2.76)                0.74   0.63 (0.24 to 1.65)
   Composite outcome†          637      0.82                          0.83 (0.54 to 1.26)                1.27   1.08 (0.71 to 1.64)

OR estimates have been omitted, and replaced with 'n/a' for 'not available', for outcomes where estimation was not possible due to a small number of events in one or more exposure groups.

\*The 'Admissions in 2015 versus 2006' column reports the odds of each outcome occurring in association with an accidental opioid overdose hospitalisation in 2015 when compared with 2006.

†The 'composite outcome' was defined as the occurrence of one or more of the following within an admission: encephalopathy, ARDS, respiratory failure, pulmonary haemorrhage, aspiration pneumonia, cardiac arrest, ventricular arrhythmia, heart failure, rhabdomyolysis, acute renal failure or death (corresponds to 'admission with ≥1 event\' under the composite outcome in [table 3](#T3){ref-type="table"}). Occurrences of the composite outcome do not equal the sum of other events, because some admissions included more than one type of event but this only counted once towards the composite outcome.

ARDS, adult respiratory distress syndrome.

We included indicator variables for the year in which each accidental opioid overdose occurred in the regression models for our primary analysis, which provided a test of whether risk of the outcome in each model was higher in the final year of our study (2015) in comparison with the initial year of the study (2006). We found the risk of encephalopathy was not elevated in 2015 in comparison to 2006 (OR 0.73; 95% CI 0.28 to 1.89) ([table 4](#T4){ref-type="table"}). In contrast, respiratory failure in association with opioid overdose was approximately three times higher in 2015 in relation to 2006 (OR 3.05; 95% CI 1.15 to 8.08), although the estimate was imprecise. While no other outcomes showed a significantly higher risk in the last year of the study, the point estimate for risk of acute renal failure was elevated but non-significant (OR 1.86; 95% CI 0.95 to 3.66). In a sensitivity analysis, an examination of the general trend in incidence of acute renal failure showed a similar elevation in risk of acute renal failure in the general population of BC (relative risk 2.38; 95% CI 2.30 to 2.47).

Adverse events in year following admissions for accidental opioid overdose {#s3d}
--------------------------------------------------------------------------

In our secondary analysis, we compared patients in the year following discharge from an accidental opioid overdose admission to controls, among a cohort of patients with long-term prescription opioid use. Encephalopathy was diagnosed in fewer than five patients in each of the cohorts in our secondary analysis (the overdose cohort and the control cohort), so we could not estimate an OR to compare overdose patients with controls for this outcome. Our analyses suggested a doubling of the odds of experiencing one of the events in our composite outcome (OR 2.15; 95% CI 1.48 to 3.12) or a serious adverse event (OR 1.97; 95% CI 1.62 to 2.39), or dying from any cause (OR 2.13; 95% CI 1.18 to 3.86), for patients in the year following a hospital admission for accidental opioid overdose, compared with controls ([table 5](#T5){ref-type="table"}). Analyses of effect measure modification (not shown) did not indicate that year of cohort entry was an effect modifier in relation to risk of our study outcomes among overdose patients in the year following an overdose relative to control patients.

###### 

Risk of neurological, respiratory, cardiac and other outcomes in 1 year following hospital admission for accidental opioid overdose in comparison to controls among patients with long-term prescription opioid use (≥180 days)

                                Events   Odds ratios           
  ----------------------------- -------- ------------- ------- ----------------------
  *Primary outcome*                                            
  Neurological:                                                
    Encephalopathy              \<5      \<5           n/a     n/a
  *Secondary outcome*                                          
  Respiratory outcomes:                                        
    Respiratory failure         14       23            12.46   6.21 (2.24 to 17.21)
    Aspiration pneumonia        5        19            5.30    2.96 (0.90 to 9.71)
    ARDS                        \<5      9             n/a     n/a
    Pulmonary haemorrhage       0        0             n/a     n/a
  Cardiac outcomes:                                            
    Cardiac arrest              0        5             n/a     n/a
    Ventricular arrhythmia      0        5             n/a     n/a
    Heart failure               9        95            1.93    0.99 (0.45 to 2.15)
  Other outcomes:                                              
    Rhabdomyolysis              5        19            5.30    3.08 (0.87 to 10.88)
    Acute renal failure         16       103           3.18    1.66 (0.90 to 3.05)
    Paraplegia or tetraplegia   \<5      6             n/a     n/a
  All-cause mortality           22       96            4.73    2.13 (1.18 to 3.86)
  Composite outcome\*           59       309           4.14    2.15 (1.48 to 3.12)
  Serious adverse events†       315      3489          2.84    1.97 (1.62 to 2.39)

OR estimates have been omitted, and replaced with 'n/a' for 'not available', for outcomes where estimation was not possible due to a small number of events in one or more exposure groups.

\*The 'composite outcome' was defined as an inpatient hospital diagnosis of one or more of the following: encephalopathy, ARDS, respiratory failure, pulmonary haemorrhage, aspiration pneumonia, cardiac arrest, ventricular arrhythmia, heart failure, rhabdomyolysis, acute renal failure or death.

†Serious adverse events were defined as all-cause hospitalisation or death.

ARDS, adult respiratory distress syndrome.

Discussion {#s4}
==========

In our study, we found that encephalopathy was diagnosed in about 3% of accidental opioid overdose admissions from 2006 to 2015, and at least one of the adverse events in our composite outcome occurred in 25% of accidental opioid overdose admissions. We found no evidence that risk of encephalopathy or other adverse outcomes was increased in readmissions in comparison to initial admissions for accidental opioid overdose. We found that risk of respiratory failure was elevated in 2015 in relation to 2006. Since reports suggest that more potent prescription and illicit opioids have been used in BC towards the end of our study period,[@R47] the apparent increase in risk of respiratory failure may reflect exposure to more potent opioids; however, this increase in risk may have occurred due to co-ingestion of other substances[@R28] or due to other factors. While the risk of acute renal failure was non-significantly elevated in 2015 compared with 2006, a sensitivity analysis indicated that this may reflect a general trend in diagnosis of acute kidney failure.[@R49] Our comparison of overdose patients to controls within a cohort of patients with long-term opioid use suggested that the risk of serious adverse events including respiratory failure and death may be elevated in the year following an accidental opioid overdose.

A potential link between opioid overdose and encephalopathy has been reported in case reports and case series.[@R3] Additionally, a prospective observational study reported that 1 of 573 patients visiting the emergency department for opioid overdose suffered from cerebral anoxia, ARDS and death,[@R4] and a retrospective chart review reported that 2 of 42 ICU patients with heroin overdose suffered from anoxemic encephalopathy and death.[@R6] Our finding that 77 (3%) of 2554 admissions related to accidental overdose included a diagnosis of encephalopathy provides additional data on this association.

We included both anoxic brain damage and toxic encephalopathy in the definition of encephalopathy in our study, because case reports raise concerns about a potential association between opioid overdose about these outcomes, and these diagnoses describe important brain injuries.[@R6] In addition, studies that use administrative health data face the limitation that coding of outcomes in the data will often not be precise, so we have included unspecified encephalopathy in the outcome definition. There is a lack of validation studies for either anoxic or toxic encephalopathy, so the specificity of the individual diagnostic codes we used and of our composite outcome is unknown. Inclusion of unspecified encephalopathy may lead to some outcome misclassification, but this definition will have a greater sensitivity to detect encephalopathy when it has occurred. It is expected that any outcome misclassification would be similar across exposure groups in our primary analysis (ie, during an initial or repeat admission for accidental opioid overdose). This type of misclassification could bias the analysis towards a null effect.[@R50]

The association between respiratory failure and accidental opioid overdose in our study appears to be consistent with a recent US study. While not directly reporting on respiratory failure, the US study found that 10.0% of emergency department visits for opioid overdose were associated with mechanical ventilation.[@R51] Our hospital admission data found that respiratory failure occurred in 9.4% of overdose admissions in 2015. In addition, a cohort study of 178 adults with opioid overdose leading to intensive care unit admission reported that 84.8% required mechanical ventilation.[@R28]

Our study provides new data on potential association between accidental opioid overdose and a range of serious adverse events. A strength of our study was that adverse events associated with overdose were collected from population data rather than adverse event reports. These data were more comprehensive than adverse event reports, because the data were collected routinely by the healthcare system rather than relying on reports from the public, healthcare providers or manufacturers and because the data available covered most of the population of the province. However, our study had some limitations. Our analysis of readmissions which occurred within 1 year of a previous admission excluded patients with adverse events in the year prior to readmission. However, this exclusion may have created selection bias by excluding patients who were more susceptible to these adverse events from the cohort of readmission patients. In addition, we analysed data on accidental opioid hospitalisations but lacked data about overdoses that did not result in a hospital admission and lacked complete information about drug exposure including illicit drug use. We included patients with long-term use of prescription opioids in our secondary analysis based on the information in available administrative health databases; however, this excluded others with long-term opioid use who lacked ongoing prescriptions of their own but used opioids prescribed to others and/or non-prescription opioids. Lastly, our analyses may have been subject to unmeasured confounders, such as co-ingestion of other drugs with opioids.

Conclusions {#s5}
===========

We found no increased risk of encephalopathy or other adverse events in repeat hospital admissions compared with initial admission for accidental opioid overdose. Our analysis suggests that accidental opioid overdoses were associated with risk of respiratory failure, and that risk of respiratory failure associated with opioid overdose was higher in 2015 compared with 2006. The risk of serious adverse events including respiratory failure and death may be elevated in the year following an accidental opioid overdose.
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